Can’t Stop, Won’t Stop the Search for Relief: Scratching the Surface of Itch and Inflammation in Moderate-to-Severe AD – Tweetorial #3

 

 

PROGRAM OVERVIEW

Although moderate-to-severe atopic dermatitis (AD) manifests on the skin’s surface, it’s far from superficial. It’s a disease that originates from the deepest interior of the immune system to profoundly destabilize all psychophysical aspects of health-related quality of life. As we have begun to unravel the mystery of the pathophysiology of AD, it is becoming clear that to be effective, treatment needs to target the proinflammatory pathways and cytokines that are the pruritogenic core of this disease. This program will review current and emerging Janus kinase (JAK) inhibitors for the treatment of atopic dermatitis.

FACULTY

Seemal R. Desai, MD
Clinical Assistant Professor of Dermatology
University of Texas Southwestern
Plano, Texas

FACULTY REVIEWER

Jonathan I. Silverberg, MD, PhD, MPH
Associate Professor of Dermatology
Director, Clinical Research & Contact Dermatitis
School of Medicine and Health Sciences
The George Washington University
Washington, District of Columbia

 

Release date: September 16, 2020
Expiration date: September 16, 2021
Estimated time to complete activity: 0.25 hour(s)

 

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from Pfizer, Inc.

TARGET AUDIENCE

This program is intended for allergists, immunologists, dermatologists, specialty advanced practice providers, and other healthcare professionals involved in the management and treatment of patients with moderate-to-severe AD.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Devise a strategy to incorporate emerging biologic monoclonal antibodies (mAbs) and JAK inhibitors into treatment plans as they become available to appropriately selected patients with moderate-to-severe AD
  • Interpret endpoint results from phase 3 clinical trials comparing the biologic dupilumab with JAK inhibitors
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 16, 2020 through September 16, 2021, participants must:

  • Read the CME information (this page)
  • Complete the pretest
  • Study the educational Tweetorial/activity
  • Complete the posttest and the evaluation form

A statement of credit will be available for immediate download upon completion of the activity evaluation form and a completed post-test with a score of 100%

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this other activity Twitter-based Tweetorial for a maximum of 0.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Seemal R. Desai, MD does not have any conflicts of interest to disclose.

Jonathan I. Silverberg, MD, PhD, MPH
Consulting Fees: AbbVie, Arena, Asana, Bluefin, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Kiniksa, Leo, Luna, Medimmune, Menlo, Novartis, Pfizer Inc., Regeneron, Sanofi Genzyme
Speakers’ Bureaus: Regeneron, Sanofi Genzyme
Contracted Research: Galderma, GlaxoSmithKline

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

Continue to Pretest